NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.62 Million EUR | 133.37% |
| 2022 | 1.55 Million EUR | 290.09% |
| 2021 | 397.72 Thousand EUR | -6.77% |
| 2020 | 426.61 Thousand EUR | 669.14% |
| 2019 | 55.46 Thousand EUR | -70.62% |
| 2018 | 188.78 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.72 Million EUR | -24.85% |
| 2023 Q4 | 3.62 Million EUR | -1.36% |
| 2023 FY | 3.62 Million EUR | 133.37% |
| 2023 Q2 | 3.67 Million EUR | 136.58% |
| 2022 FY | 1.55 Million EUR | 290.09% |
| 2022 Q4 | 1.55 Million EUR | 87.46% |
| 2022 Q2 | 827.63 Thousand EUR | 0.0% |
| 2021 FY | 397.72 Thousand EUR | -6.77% |
| 2021 Q2 | 1.49 Million EUR | 0.0% |
| 2020 FY | 426.61 Thousand EUR | 669.14% |
| 2019 FY | 55.46 Thousand EUR | -70.62% |
| 2018 FY | 188.78 Thousand EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | 47.617% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 97.237% |
| Adocia SA | 31.87 Million EUR | 88.639% |
| Aelis Farma SA | 13.08 Million EUR | 72.319% |
| Biophytis S.A. | 15.84 Million EUR | 77.155% |
| Advicenne S.A. | 24.37 Million EUR | 85.147% |
| genOway Société anonyme | 14.45 Million EUR | 74.96% |
| IntegraGen SA | 5.97 Million EUR | 39.451% |
| Medesis Pharma S.A. | 6.42 Million EUR | 43.657% |
| Neovacs S.A. | 3.71 Million EUR | 2.463% |
| Plant Advanced Technologies SA | 6.78 Million EUR | 46.616% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -9.383% |
| Sensorion SA | 13.22 Million EUR | 72.627% |
| Theranexus Société Anonyme | 5.01 Million EUR | 27.82% |
| TME Pharma N.V. | 2.78 Million EUR | -30.007% |
| Valbiotis SA | 13.7 Million EUR | 73.587% |
| TheraVet SA | 1.48 Million EUR | -143.818% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 82.311% |
| argenx SE | 402.79 Million EUR | 99.101% |
| BioSenic S.A. | 32.26 Million EUR | 88.778% |
| Celyad Oncology SA | 9.97 Million EUR | 63.713% |
| DBV Technologies S.A. | 38.74 Million USD | 90.655% |
| Galapagos NV | 1.56 Billion EUR | 99.768% |
| Genfit S.A. | 105.92 Million EUR | 96.582% |
| GeNeuro SA | 20.13 Million EUR | 82.022% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | 57.958% |
| Innate Pharma S.A. | 132.29 Million EUR | 97.263% |
| Inventiva S.A. | 101.59 Million EUR | 96.436% |
| MaaT Pharma SA | 22.46 Million EUR | 83.883% |
| MedinCell S.A. | 77.77 Million EUR | 95.344% |
| Nanobiotix S.A. | 95.74 Million EUR | 96.218% |
| Onward Medical N.V. | 25.69 Million EUR | 85.911% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 85.59% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 93.871% |
| Oxurion NV | 19.73 Million EUR | 81.654% |
| Pharming Group N.V. | 228.28 Million EUR | 98.414% |
| Poxel S.A. | 53.9 Million EUR | 93.283% |
| GenSight Biologics S.A. | 34.72 Million EUR | 89.574% |
| Transgene SA | 26.51 Million EUR | 86.346% |
| Financière de Tubize SA | 123.65 Million EUR | 97.072% |
| UCB SA | 6.56 Billion EUR | 99.945% |
| Valneva SE | 341.14 Million EUR | 98.939% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | 20.372% |